• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫介导性多发性神经病新总体残疾量表的临床计量学评估

Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.

作者信息

Merkies I S J, Schmitz P I M, van der Meché F G A, Samijn J P A, van Doorn P A

机构信息

Department of Neurology, University Hospital Rotterdam/Erasmus University, dr Molewaterplein, Rotterdam, Netherlands.

出版信息

J Neurol Neurosurg Psychiatry. 2002 May;72(5):596-601. doi: 10.1136/jnnp.72.5.596.

DOI:10.1136/jnnp.72.5.596
PMID:11971045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1737884/
Abstract

OBJECTIVES

To determine the validity, reliability, and responsiveness of a new overall disability sum score in immune mediated polyneuropathies.

METHODS

Three impairment measures (MRC sum score, sensory sum score, grip strength (Vigorimeter)) and three disability scales (an overall disability sum score (ODSS), Hughes' functional scale (f score), Rankin scale) were assessed in a cross sectional group of 113 clinically stable patients (83 with Guillain-Barré syndrome, 22 with chronic inflammatory demyelinating polyneuropathy (CIDP), eight with a gammopathy related polyneuropathy). The ODSS was also used serially in 20 patients with recently diagnosed Guillain-Barré syndrome (n = 7) or CIDP (n = 13) and changing clinical conditions. Multiple regression studies were performed to compare the impact of impairment disturbances (independent variables) on the various disability scales (dependent variable).

RESULTS

Moderate to good construct validity (stable group: Spearman's rank test (absolute values), r = 0.41-0.79; longitudinal group: multiple correlation coefficient, R = 0.69-0.89; p < 0.006 for all associations) and reliability (intraclass correlation coefficient, R = 0.90-0.95; p < 0.0001) were demonstrated for the ODSS. Its SRM values were high (> 0.8), indicating good responsiveness. Impairment measures accounted for a higher variance proportion of the ODSS compared with the f score and Rankin (R = 0.64 v 0.56 and 0.45, respectively).

CONCLUSIONS

All clinimetric requirements were met by the overall (arm and leg) disability sum score in immune mediated polyneuropathies. Its use is therefore suggested in evaluating immune mediated polyneuropathies.

摘要

目的

确定免疫介导性多发性神经病新的整体残疾总分的有效性、可靠性和反应性。

方法

对113例临床稳定的患者(83例吉兰 - 巴雷综合征、22例慢性炎症性脱髓鞘性多发性神经病(CIDP)、8例与丙种球蛋白病相关的多发性神经病)的横断面组进行了三项损伤测量(医学研究委员会总分、感觉总分、握力(测力计))和三项残疾量表(整体残疾总分(ODSS)、休斯功能量表(f评分)、兰金量表)评估。ODSS也在20例近期诊断为吉兰 - 巴雷综合征(n = 7)或CIDP(n = 13)且临床状况不断变化的患者中进行了连续使用。进行了多元回归研究,以比较损伤障碍(自变量)对各种残疾量表(因变量)的影响。

结果

ODSS显示出中度至良好的结构效度(稳定组:斯皮尔曼等级检验(绝对值),r = 0.41 - 0.79;纵向组:复相关系数,R = 0.69 - 0.89;所有关联p < 0.006)和可靠性(组内相关系数,R = 0.90 - 0.95;p < 0.0001)。其标准化反应均值(SRM)值较高(> 0.8),表明反应性良好。与f评分和兰金量表相比,损伤测量占ODSS的方差比例更高(分别为R = 0.64对0.56和0.45)。

结论

免疫介导性多发性神经病的整体(手臂和腿部)残疾总分满足所有临床测量要求。因此建议在评估免疫介导性多发性神经病时使用该量表。

相似文献

1
Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.免疫介导性多发性神经病新总体残疾量表的临床计量学评估
J Neurol Neurosurg Psychiatry. 2002 May;72(5):596-601. doi: 10.1136/jnnp.72.5.596.
2
Connecting impairment, disability, and handicap in immune mediated polyneuropathies.免疫介导性多发性神经病中连接损伤、残疾和障碍的关系
J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):99-104. doi: 10.1136/jnnp.74.1.99.
3
Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies.评估健康个体及免疫介导性多发性神经病患者的握力。
Muscle Nerve. 2000 Sep;23(9):1393-401. doi: 10.1002/1097-4598(200009)23:9<1393::aid-mus10>3.0.co;2-o.
4
Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients' own clinical judgement in immune-mediated polyneuropathies.更贴近患者:INCAT整体残疾总分在免疫介导性多发性神经病中与患者自身的临床判断关联更强。
J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):970-2. doi: 10.1136/jnnp.2005.076174. Epub 2006 Mar 20.
5
Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group.免疫介导性多发性神经病新感觉量表的心理测量评估。炎症性神经病病因与治疗(INCAT)小组。
Neurology. 2000 Feb 22;54(4):943-9. doi: 10.1212/wnl.54.4.943.
6
Comparison between impairment and disability scales in immune-mediated polyneuropathies.免疫介导性多发性神经病中损伤与残疾量表的比较。
Muscle Nerve. 2003 Jul;28(1):93-100. doi: 10.1002/mus.10410.
7
Quality of life complements traditional outcome measures in immune-mediated polyneuropathies.生活质量补充了免疫介导性多发性神经病的传统疗效指标。
Neurology. 2002 Jul 9;59(1):84-91. doi: 10.1212/wnl.59.1.84.
8
Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.免疫介导性多发性神经病中的疲劳。欧洲炎性神经病病因与治疗(INCAT)小组。
Neurology. 1999 Nov 10;53(8):1648-54. doi: 10.1212/wnl.53.8.1648.
9
Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies.免疫介导性多发性神经病新残疾量表的心理测量评估
Muscle Nerve. 2002 Mar;25(3):370-7. doi: 10.1002/mus.10045.
10
Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies.与抗髓鞘相关糖蛋白(MAG)抗体相关的多发性神经病的长期残疾及预后因素
Int J Neurosci. 2017 May;127(5):439-447. doi: 10.1080/00207454.2016.1191013. Epub 2016 Jun 7.

引用本文的文献

1
Minimal Clinically Important Difference for the Jamar Hand Grip Dynamometer in CIDP: A Korea-UK Study.慢性炎症性脱髓鞘性多发性神经病中 Jamar 握力计的最小临床重要差异:一项韩英研究
Eur J Neurol. 2025 Aug;32(8):e70335. doi: 10.1111/ene.70335.
2
Integrated treatment approach to Miller Fisher syndrome, a variant of Guillain-Barre syndrome - A case report.格林-巴利综合征变异型米勒-费雪综合征的综合治疗方法——病例报告
J Ayurveda Integr Med. 2025 Jun 27;16(4):101159. doi: 10.1016/j.jaim.2025.101159.
3
Validity and Responsiveness of Balance Measurements Using Posturography in Patients With Immune-Mediated Neuropathies.姿势描记法对免疫介导性神经病患者平衡测量的有效性和反应性
J Peripher Nerv Syst. 2025 Jun;30(2):e70031. doi: 10.1111/jns.70031.
4
Early therapy initiation is crucial in chronic inflammatory demyelinating polyneuropathy: prospective multimodal data from the German INHIBIT registry.早期开始治疗在慢性炎症性脱髓鞘性多发性神经病中至关重要:来自德国INHIBIT注册研究的前瞻性多模态数据。
J Neurol. 2025 Jan 7;272(1):100. doi: 10.1007/s00415-024-12860-w.
5
Assessing axonal pathology and disease progression in chronic inflammatory demyelinating polyneuropathy using corneal confocal microscopy.使用角膜共聚焦显微镜评估慢性炎症性脱髓鞘性多发性神经病中的轴突病理学和疾病进展。
J Neurol. 2024 Dec 12;272(1):51. doi: 10.1007/s00415-024-12812-4.
6
Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial.利妥昔单抗对比安慰剂治疗慢性炎性脱髓鞘性多发性神经根神经病:一项随机试验。
Brain. 2025 Apr 3;148(4):1112-1121. doi: 10.1093/brain/awae400.
7
Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial.透明质酸酶辅助的10%皮下免疫球蛋白作为慢性炎症性脱髓鞘性多发性神经根神经病维持治疗的长期安全性和耐受性:ADVANCE-CIDP 3试验结果
J Peripher Nerv Syst. 2024 Dec;29(4):441-452. doi: 10.1111/jns.12672. Epub 2024 Nov 11.
8
Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy.炎性神经病联盟基础(INCbase):一项全球前瞻性观察队列研究方案,旨在开发一种预测慢性炎症性脱髓鞘性多发性神经病治疗反应的模型。
BMC Neurol. 2024 Oct 25;24(1):415. doi: 10.1186/s12883-024-03903-w.
9
Different Patterns of Autoantibody Secretion by Peripheral Blood Mononuclear Cells in Autoimmune Nodopathies.自身免疫性结节病外周血单个核细胞自身抗体分泌的不同模式。
Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200295. doi: 10.1212/NXI.0000000000200295. Epub 2024 Aug 22.
10
Maintenance Intravenous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: 18-Month Post-marketing Surveillance in 103 Patients.慢性炎症性脱髓鞘性多发性神经病的维持性静脉注射免疫球蛋白治疗:103例患者的18个月上市后监测
Intern Med. 2025 Feb 15;64(4):535-541. doi: 10.2169/internalmedicine.3661-24. Epub 2024 Jul 18.

本文引用的文献

1
Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies.评估健康个体及免疫介导性多发性神经病患者的握力。
Muscle Nerve. 2000 Sep;23(9):1393-401. doi: 10.1002/1097-4598(200009)23:9<1393::aid-mus10>3.0.co;2-o.
2
Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group.免疫介导性多发性神经病新感觉量表的心理测量评估。炎症性神经病病因与治疗(INCAT)小组。
Neurology. 2000 Feb 22;54(4):943-9. doi: 10.1212/wnl.54.4.943.
3
Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.免疫介导性多发性神经病中的疲劳。欧洲炎性神经病病因与治疗(INCAT)小组。
Neurology. 1999 Nov 10;53(8):1648-54. doi: 10.1212/wnl.53.8.1648.
4
Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome.吉兰-巴雷综合征3至6年后的残留身体状况和日常生活情况
Neurology. 1999 Jul 22;53(2):409-10. doi: 10.1212/wnl.53.2.409.
5
Scale development and Guy's Neurological Disability Scale.量表开发与盖伊神经功能障碍量表
J Neurol. 1999 Mar;246(3):226. doi: 10.1007/s004150050340.
6
Impact of neurologic signs and symptoms on functional status in peripheral neuropathies.
Neurology. 1999 Jan 1;52(1):151-6. doi: 10.1212/wnl.52.1.151.
7
Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies.吉兰-巴雷综合征、慢性炎性脱髓鞘性多发性神经根神经病及其他慢性免疫介导性神经病。
Curr Opin Neurol. 1998 Oct;11(5):497-513. doi: 10.1097/00019052-199810000-00013.
8
Paraproteinaemic neuropathies.副蛋白血症性神经病
Baillieres Clin Neurol. 1996 Mar;5(1):219-32.
9
Evaluating neurological outcome measures: the bare essentials.评估神经学结果指标:基本要素
J Neurol Neurosurg Psychiatry. 1996 Feb;60(2):127-30. doi: 10.1136/jnnp.60.2.127.
10
Evaluating measurement responsiveness.
J Rheumatol. 1995 Jun;22(6):1191-2.